Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

Acta Oncologica

Volumn 48, Issue 4, 2009, Pages 621-624

  Wolter, Pascal ^a   Beuselinck, Benoit ^a   Pans, Steven ^a   Schffski, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; SUNITINIB; ZOLEDRONIC ACID; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE;

ADULT; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOTHYROIDISM; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LETTER; LIVER METASTASIS; LUNG EMBOLISM; LUNG INFECTION; LUNG METASTASIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SALVAGE THERAPY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; BONE TUMOR; DISEASE COURSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; PAIN; PATHOLOGY;

BONE NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEPHRECTOMY; PAIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65549147186     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802609574     Document Type: Letter

References (10)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;/2:/471-8.
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;/9:/327-37.
3. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;/101:/3597-605.
4. Pfizer Inc., data on file
5. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future trial development. Nat Rev Drug Discov 2007;/6:/734-45.
6. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;/143:/313-4.
7. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007;/25:/1107-13.
8. Blay JY, George S, Casali PG Le Cesne A, Morgan JA, Tyler A, et al. Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Ann Oncol 2006;17(Suppl 9):508P (Abstract).
9. Escudier B, Roigas J, Gillessen S, Srinivas S, Pisa P, Vogelzang N, et al. Continuous daily administration of sunitinib malate (SU11248)-phase II study in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2006;17(Suppl 9):436O (Abstract).
10. MancusoMR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara Yao VJ, et al. Rapid vascular regrowth in tumours after reversal of VEGF inhibition. J Clin Invest 2006;/116:/ 2610-21.